Sec. 25. Reimbursement requirements; notice.

125 words·~1 min read·/il/chapter-410/act-416/25

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)A reimbursement under the program at a trial site that conducts clinical trials must:

(1)be reviewed and approved by the institutional review board associated with the

clinical trial for which the reimbursement is provided; and

(2)comply with applicable federal and State laws.

(b)The independent third-party organization operating the program is not required to obtain approval from an institutional review board with respect to the financial eligibility of a subject who is medically eligible for a clinical trial.

(c)The independent third-party organization operating the program shall provide written notice to a subject on:

(1)the nature, availability, and scope of the ancillary financial support under the

program; and

(2)the program's general guidelines on financial eligibility.